Immix Biopharma Company Insiders

IMMX Stock  USD 6.85  0.12  1.78%   
Immix Biopharma's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Immix Biopharma suggests that vertually all insiders are extremely bullish. Immix Biopharma employs about 18 people. The company is managed by 13 executives with a total tenure of roughly 42 years, averaging almost 3.0 years of service per executive, having 1.38 employees per reported executive.

Insider Sentiment 100

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2025-12-10Ilya M RachmanAcquired 746 @ 6.67View
2025-09-17Ilya M RachmanAcquired 2500 @ 2.02View
2025-09-16Gabriel S MorrisAcquired 2600 @ 1.97View
2025-06-18Ilya M RachmanAcquired 2178 @ 2.29View
Monitoring Immix Biopharma's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immix Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.
For more information on how to buy Immix Stock please use our How to Invest in Immix Biopharma guide.

Immix Biopharma Management Team Effectiveness

The company has return on total asset (ROA) of (0.6648) % which means that it has lost $0.6648 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8255) %, meaning that it created substantial loss on money invested by shareholders. Immix Biopharma's management efficiency ratios could be used to measure how well Immix Biopharma manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.89 in 2026. Return On Capital Employed is likely to rise to -1.74 in 2026. At this time, Immix Biopharma's Net Tangible Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 3.3 M in 2026, whereas Total Assets are likely to drop slightly above 14.2 M in 2026.
Common Stock Shares Outstanding is likely to rise to about 34.2 M in 2026, whereas Net Loss is likely to drop (7.8 M) in 2026. Immix Biopharma has a total of 52.96 Million outstanding shares. Immix Biopharma secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
2020-03-31
Previous Quarter
30 M
Current Value
31.9 M
Avarage Shares Outstanding
16.4 M
Quarterly Volatility
9.4 M
 
Covid
 
Interest Hikes
Some institutional investors establish a significant position in stocks such as Immix Biopharma in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Immix Biopharma, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Immix Biopharma Workforce Comparison

Immix Biopharma is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 823. Immix Biopharma holds roughly 18.0 in number of employees claiming about 2.19% of equities under Health Care industry.

Immix Biopharma Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immix Biopharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immix Biopharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Immix Biopharma insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
 
Interest Hikes
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-12-01
4.0
4
1
 197,159 
 60,000 
2022-09-01
4.0
8
2
 596,000 
 400.00 
2021-12-01
0.6875
11
16
 5,321,653 
 879,000 

Immix Biopharma Notable Stakeholders

An Immix Biopharma stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Immix Biopharma often face trade-offs trying to please all of them. Immix Biopharma's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Immix Biopharma's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Denise BrunsHead RegulatoryProfile
David MBBSChief TherapyProfile
Michael GrabowChief OfficerProfile
Gabriel BACFO DirectorProfile
Gerhard BauerHead ManufacturingProfile
MD FFPMChief DevelopmentProfile
MBA MDChairman CoFounderProfile
Ben JDExecutive CounselProfile
JD MBACoFounderProfile
David MarksChief TherapyProfile
Nandan BSManufacturing ChemistryProfile
Mel DavisPickettHead DevelopmentProfile
DSc MSEScientific CoFounderProfile
String symbol = request.getParameter("s");

About Immix Biopharma Management Performance

The success or failure of an entity such as Immix Biopharma often depends on how effective the management is. Immix Biopharma management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Immix management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Immix management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.85)(0.89)
Return On Capital Employed(1.83)(1.74)
Return On Assets(0.85)(0.89)
Return On Equity(1.88)(1.78)
Please note, the imprecision that can be found in Immix Biopharma's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Immix Biopharma. Check Immix Biopharma's Beneish M Score to see the likelihood of Immix Biopharma's management manipulating its earnings.

Immix Biopharma Workforce Analysis

Traditionally, organizations such as Immix Biopharma use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Immix Biopharma within its industry.

Immix Biopharma Manpower Efficiency

Return on Immix Biopharma Manpower

Revenue Per Employee0.0
Revenue Per Executive0.0
Net Loss Per Employee1.2M
Net Loss Per Executive1.7M
Working Capital Per Employee639.5K
Working Capital Per Executive885.4K

Additional Tools for Immix Stock Analysis

When running Immix Biopharma's price analysis, check to measure Immix Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immix Biopharma is operating at the current time. Most of Immix Biopharma's value examination focuses on studying past and present price action to predict the probability of Immix Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immix Biopharma's price. Additionally, you may evaluate how the addition of Immix Biopharma to your portfolios can decrease your overall portfolio volatility.